Asset Details
Do you wish to reserve the book?
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
Do you wish to request the book?
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
2024
Overview
Background
Medications for opioid use disorder (MOUD), including buprenorphine, are effective treatments for opioid use disorder (OUD) and reduce risk for overdose and death. Buprenorphine can be prescribed in outpatient primary care settings to treat OUD; however, prior research suggests adherence to buprenorphine in these settings can be low. The purpose of this study was to identify the rates of and factors associated with buprenorphine adherence among patients with OUD in the first six months after a new start of buprenorphine.
Methods
Data were extracted from the electronic health record (EHR) from a large integrated health system in the upper Midwest. Patients with OUD (
N
= 345; Mean age = 37.6 years, SD 13.2; 61.7% male; 78% White) with a new start of buprenorphine between March 2019 and July 2021 were included in the analysis. Buprenorphine adherence in the first six months was defined using medication orders; the proportion of days covered (PDC) with a standard cut-point of 80% was used to classify patients as adherent or non-adherent. Demographic (e.g., age, sex, race and ethnicity, geographic location), service (e.g., encounters, buprenorphine formulations and dosage) and clinical (e.g., diagnoses, urine toxicology screens) characteristics were examined as factors that could be related to adherence. Analyses included logistic regression with adherence group as a binary outcome.
Results
Less than half of patients were classified as adherent to buprenorphine (44%). Adjusting for other factors, male sex (OR = 0.34, 95% CI = 0.20, 0.57,
p
< .001) and having an unexpected positive for opioids on urine toxicology (OR = 0.42, 95% CI = 0.21, 0.83,
p
< .014) were associated with lower likelihood of adherence to buprenorphine, whereas being a former smoker (compared to a current smoker; OR = 1.82, 95% CI = 1.02, 3.27,
p
= .014) was associated with greater likelihood of being adherent to buprenorphine.
Conclusions
These results suggest that buprenorphine adherence in primary care settings may be low, yet male sex and smoking status are associated with adherence rates. Future research is needed to identify the mechanisms through which these factors are associated with adherence.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Buprenorphine - therapeutic use
/ Drug use
/ Female
/ Humans
/ Male
/ Medicaid
/ Medicare
/ Medications for opioid Use Disorder
/ Medicine
/ Mental health in primary care
/ Methods
/ Narcotic Antagonists - therapeutic use
/ Opiate Substitution Treatment - statistics & numerical data
/ Opioid-Related Disorders - drug therapy
/ Opioid-Related Disorders - epidemiology
